Lilly Complements its Drug Discovery Research with Integrated Cellular Screening System from Amersham Biosciences

11-Nov-2003

Amersham, a world leader in medical diagnostics and in life sciences, announces that Eli Lilly and Company has purchased an integrated suite of cellular screening technology and licenses to help in the identification of potential therapeutics in its drug discovery program.

In addition to the purchase of an IN Cell Analyzer 3000 high-throughput sub-cellular imaging system, Lilly has signed an agreement with Amersham for rights to Aequorea Victoria Green Fluorescent Protein (GFP). Furthermore, Lilly has secured rights to operate under BioImage's Redistribution(TM) patent portfolio for monitoring intracellular signalling pathways, including protein translocation.

Utilizing the advanced imaging quality and speed of the IN Cell Analyzer 3000 system in conjunction with the Aequorea Victoria GFP and Redistribution helps speed cellular screening capability and, ultimately, aid the discovery of new pharmaceuticals by examining disease-related targets in an informative biological context.

"We are delighted to be working with Lilly in this area," said Mike Evans, Vice President of Marketing and Strategy, Discovery Systems at Amersham Biosciences, "Lilly's decision to utilize GFP and Redistribution technology together with the IN Cell Analyzer 3000 reflects the trend in the pharmaceutical industry towards generating biological information earlier in the drug development process to speed up the time to market. We look forward to working closely with Lilly in the future."

"I am pleased that Lilly has chosen Redistribution to enhance its drug discovery program." said Dr. Patrik Dahlén, CEO of BioImage. "We are proud to have contributed with the Redistribution technology and look forward to its further utilization in drug discovery."

https://www.bionity.com/en/news/30930/lilly-complements-its-drug-discovery-research-with-integrated-cellular-screening-system-from-amersham-biosciences.html